NASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis $2.50 +0.12 (+5.04%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.35▼$2.5250-Day Range$2.21▼$3.3552-Week Range$1.28▼$5.51Volume154,940 shsAverage Volume212,004 shsMarket Capitalization$211.25 millionP/E RatioN/ADividend YieldN/APrice Target$13.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Century Therapeutics alerts: Email Address Century Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside452.0% Upside$13.80 Price TargetShort InterestBearish8.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingSelling Shares$48,939 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.94) to ($1.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.30 out of 5 starsMedical Sector775th out of 936 stocksBiological Products, Except Diagnostic Industry132nd out of 154 stocks 3.4 Analyst's Opinion Consensus RatingCentury Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Century Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.34% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.Change versus previous monthShort interest in Century Therapeutics has recently increased by 60.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSC. Previous Next 2.5 News and Social Media Coverage News SentimentCentury Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Century Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,939.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Century Therapeutics is held by insiders.Percentage Held by Institutions50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Century Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Century Therapeutics are expected to decrease in the coming year, from ($1.94) to ($1.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Century Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Century Therapeutics Stock (NASDAQ:IPSC)Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More IPSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSC Stock News HeadlinesJuly 16, 2024 | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) & Anavex Life Sciences (NASDAQ:AVXL) Financial ComparisonJune 3, 2024 | globenewswire.comCentury Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual MeetingJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics on Promising CNTY-101 Prospects and Strong Financial FootingMay 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics Amid Promising Trials and Strategic AcquisitionsMay 10, 2024 | finance.yahoo.comCentury Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...May 10, 2024 | finance.yahoo.comCentury Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual MeetingMay 9, 2024 | investorplace.comIPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 9, 2024 | globenewswire.comCentury Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesApril 26, 2024 | investing.comCentury Therapeutics executive sells shares worth over $15kApril 23, 2024 | finance.yahoo.comCentury Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 23, 2024 | globenewswire.comCentury Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics Amidst Strong Financial Backing and Promising Clinical AdvancesApril 14, 2024 | uk.investing.comCentury Therapeutics shares target cut, retains OverweightApril 12, 2024 | msn.comCentury Therapeutics Gears Up to Conquer Highly Unmet Areas in Autoimmune Disease TreatmentsApril 12, 2024 | markets.businessinsider.comCentury Therapeutics: Hold Rating Justified Amid Strategic Acquisition and Ongoing Clinical TrialsApril 11, 2024 | globenewswire.comCentury Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsSee More Headlines Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IPSC CUSIPN/A CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Target$13.80 High Stock Price Target$24.00 Low Stock Price Target$5.00 Potential Upside/Downside+472.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-136,670,000.00 Net Margins-9,742.41% Pretax Margin-9,693.21% Return on Equity-59.74% Return on Assets-32.51% Debt Debt-to-Equity RatioN/A Current Ratio12.44 Quick Ratio12.44 Sales & Book Value Annual Sales$2.23 million Price / Sales91.32 Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book0.79Miscellaneous Outstanding Shares84,500,000Free Float78,755,000Market Cap$203.65 million OptionableOptionable Beta1.40 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Brent Pfeiffenberger M.B.A.Pharm.D., CEO & DirectorDr. Adrienne Farid Ph.D. (Age 62)COO & Head of Early Development Comp: $670.29kDr. Gregory Russotti Ph.D. (Age 57)Chief Technology & Manufacturing Officer Comp: $852.56kMr. Douglas Carr CPAInterim Principal Financial Officer, Senior VP of Finance & Operations and SecretaryMr. Kenneth J. Dow J.D.Senior VP of General CounselDr. Shane Williams Ph.D.Chief People OfficerDr. Hyam I. Levitsky M.D. (Age 66)President of Research & Development Comp: $502.12kMichael Naso Ph.D.Senior VP of Cell EngineeringDr. Nick Trede M.D.Ph.D., Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsInvivydNASDAQ:IVVDKinnate BiopharmaNASDAQ:KNTEbluebird bioNASDAQ:BLUENkartaNASDAQ:NKTXAlloVirNASDAQ:ALVRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 78,088 shares on 7/26/2024Ownership: 0.176%Gregory RussottiSold 200 sharesTotal: $500.00 ($2.50/share)Gregory RussottiSold 5,000 sharesTotal: $14,200.00 ($2.84/share)Gregory RussottiSold 5,000 sharesTotal: $15,000.00 ($3.00/share)Jacobs Levy Equity Management Inc.Bought 192,915 shares on 5/16/2024Ownership: 0.453%View All Insider TransactionsView All Institutional Transactions IPSC Stock Analysis - Frequently Asked Questions How have IPSC shares performed this year? Century Therapeutics' stock was trading at $3.32 on January 1st, 2024. Since then, IPSC shares have decreased by 24.7% and is now trading at $2.50. View the best growth stocks for 2024 here. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.05. The business had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.30 million. Century Therapeutics had a negative trailing twelve-month return on equity of 59.74% and a negative net margin of 9,742.41%. When did Century Therapeutics IPO? Century Therapeutics (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Top institutional shareholders of Century Therapeutics include Bank of New York Mellon Corp (0.18%). Insiders that own company stock include Versant Venture Capital Vi, L, Douglas Carr, Gregory Russotti, Luis Borges and Adrienne Farid. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IPSC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
